middle.news
Alterity Therapeutics advances ATH434 with FDA Phase 3 trial clarity and patent extension
3:33pm on Friday 28th of August, 2026 AEST
•
Healthcare
Read Story
Alterity Therapeutics advances ATH434 with FDA Phase 3 trial clarity and patent extension
3:33pm on Friday 28th of August, 2026 AEST
Key Points
Revenue up 285% to A$1.72 million, mainly interest income
Net loss nearly doubled to A$23.4 million
FDA confirms single pivotal Phase 3 trial design for ATH434 in MSA
Strong cash position of A$37.3 million plus R&D tax incentive refund
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE